NDLI: Trastuzumab-induced cardiotoxicity.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Moss, Lisa Stegall Starbuck, Mandy Fields Mayer, Deborah K. Harwood, Elaine Brooks Glotzer, Jana
Description	Country affiliation: United States Author Affiliation: Moss LS ( Duke Health Systems, Duke Oncology Network, Durham, NC, USA. lisa.moss@duke.edu)
Abstract	PURPOSE/OBJECTIVES: To review trastuzumab-related cardiotoxic effects in the breast cancer adjuvant setting, present a system for pretreatment screening for cardiovascular risk factors, describe monitoring recommendations, provide a tool to facilitate adherence to monitoring guidelines, and discuss implications for patient education. DATA SOURCES: Literature regarding cardiotoxicity and trastuzumab in breast cancer. DATA SYNTHESIS: Trastuzumab was approved in 2006 for use in the adjuvant setting. A small percentage of women (approximately 4%) developed heart failure during or after treatment. However, the trials excluded women with cardiac disease. Current screening for cardiotoxicity relies on sequential left ventricular function measurements with either echocardiography or multigated acquisition scanning at baseline and every three months. Treatment modifications are recommended if changes from baseline are detected. Long-term and late effects have yet to be determined. CONCLUSIONS: Although a small number of women experienced cardiotoxicity in the adjuvant setting, an increase may be seen because women with preexisting heart disease receive this treatment. Guidelines and tools will be helpful for appropriate and consistent screening of cardiac risk factors and disease prior to initiation of trastuzumab and for monitoring during and after administration. IMPLICATIONS FOR NURSING: Nurses are instrumental in assessing, monitoring, and treating women receiving trastuzumab. Implementing guidelines to promote adherence to recommended monitoring is important in the early detection of cardiotoxicity in this population. Educating women about their treatment and side effects is an important aspect of care.
File Format	HTM / HTML
ISSN	0190535X
Issue Number	6
Volume Number	36
e-ISSN	15380688
Journal	Oncology Nursing Forum
Language	English
Publisher	Oncology Nursing Society
Publisher Date	2009-11-01
Publisher Place	United States
Access Restriction	Subscribed
Subject Keyword	Discipline Nursing Discipline Oncology Antibodies, Monoclonal Adverse Effects Antineoplastic Agents Breast Neoplasms Drug Therapy Nursing Heart Diseases Chemically Induced Antibodies, Monoclonal, Humanized Epidemiology Female Humans Oncology Nursing Risk Factors Trastuzumab Journal Article Review
Content Type	Text
Resource Type	Article
Subject	Oncology (nursing)

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in